CTTACC 2027

MARK YOUR CALENDAR
MAY 2-5, 2027 | SCOTTSDALE, AZ
Omni Scottsdale Resort & Spa at Montelucia

Registration is now open!

Registration includes 3 days of educational and focus group sessions, PLUS all meals, receptions and dinners!

Poster session / Abstract Submission - Open Now - Deadline to Submit is March 14, 2025

We are looking for poster presentations in the topic areas of:
Cellular and regenerative therapies in trauma and critical care medicine.
Transfusion medicine and novel products or devices for critically injured patients.
Fundamental scientific presentations in thewe topic areas are also encouraged.

Presented by the UCSF Department of Laboratory Medicine and UCSF Center for Research in Transfusion Medicine and Cellular Therapies

Co-hosted by the Uniformed Services University

This conference represents the seventh installment of the conference Cellular Therapies and Transfusion Medicine in Trauma and Critical Care Medicine (CTTACC) series. CTTACC is a biennial conference that since its inception has served as a unique multidisciplinary forum dedicated to advancing transformative therapies for trauma, critical illness, and military medicine. We firmly believe that cellular therapies, regenerative medicine approaches, innovative blood products, and adjuncts to resuscitation represent some of the most promising frontiers in modern transfusion medicine and have the potential to dramatically improve outcomes for patients suffering from traumatic injury, hemorrhagic shock, traumatic brain injury, sepsis, acute respiratory distress syndrome, and multiple organ failure.

Previous conferences have catalyzed numerous cross-disciplinary collaborations, generated new research partnerships, supported successful grant applications, and facilitated the development of both preclinical and clinical studies. By bringing together diverse stakeholders from academia, industry, government, and healthcare, CTTACC has played a pivotal role in accelerating the translation of innovative therapies from the laboratory to the bedside.

Our mission is to support and advance the development, evaluation, and clinical translation of novel therapeutics for trauma and critical care medicine. The conference provides a collaborative environment where experts can openly discuss emerging science, technological innovations, regulatory pathways, manufacturing challenges, and clinical implementation strategies.

The meeting will convene leaders and innovators from across the spectrum of transfusion medicine, cellular therapy, regenerative medicine, military medicine, biotechnology, and critical care, including blood banks, cell therapy producers, clinicians, surgeon-scientists, physician scientists, translational researchers, industry partners, and representatives from the FDA, AFIRM, MTEC, NIH, AABB, DARPA, BARDA, and the Department of Defense.

Key Topic Areas

  • Military Health Session: Advancing the care of combat casualties through discussions of cutting-edge research, operational medicine, innovative therapeutics, and lessons learned from military and civilian trauma systems.Transfusion medicine in trauma and critical care
  • Cellular therapies and gene-modified cellular therapeutics for trauma and critical care
  • Exosomes, extracellular vesicles, and lipid nanoparticle technologies and their application to trauma
  • Plasma and blood-derived regenerative biologics
  • Platelet and Platelet Derived Products
  • Dried blood products, platelets, plasma, and next-generation hemostatic agents
  • Novel therapies for traumatic brain injury and neurotrauma
  • Precision medicine, biomarkers, and multi-omics approaches in trauma
  • Stem cell-derived blood products and next-generation blood manufacturing
  • Translational science, commercialization, and regulatory pathways
  • FDA perspectives on emerging biologics and advanced therapeutics
  • Artificial intelligence, bioengineering, and enabling technologies in critical care
  • Public-private partnerships, funding and strategies for accelerating clinical translation
  • Translational Innovation Session: From Oncology to Trauma and Critical Care — Exploring how breakthrough technologies developed in oncology, including liquid biopsy, cell engineering, AI-driven therapeutic design, and precision medicine, can be adapted to transform the diagnosis, monitoring, and treatment of trauma and critically ill patients.
  • CTTACC Working Group 1: Prehospital Blood – Advancing the mechanistic understanding of prehospital blood resuscitation, expanding its application across trauma and other hemorrhagic conditions, addressing economic and supply-chain challenges, and developing precision, evidence-based strategies to deliver the right blood product to the right patient at the right time.
  • CTTACC Working Group 2: Cellular Therapeutics in Trauma and Critical Care Addressing challenges in pre-IND development, cell product manufacturing and quality control, commercialization pathways, storage and transport logistics, and clinical trials and implementation in complex trauma and critically ill patient populations.
  • Together, these discussions will address current scientific advances, identify critical gaps in knowledge, and define strategies to overcome barriers to translation in a field where therapeutic options remain limited but opportunities for innovation are virtually limitless. Through the exchange of ideas and development of new collaborations, CTTACC aims to accelerate the delivery of life-saving therapies to both civilian and military patients worldwide.

Featured Speakers

Maj.Gen Clinton K Murray MD
Vice Admiral Darin K Via
Nobel Laureate Randy Schekman PhD

Kenneth Bertram, MD PhD – Wake Forest/AFIRM
Vikhyat Bebarta, MD – CU Anschutz
Scott Bratman, MD – RMP UHN
Laura Brosch, PhD – USU (COL Ret.)
Michael Busch, MD PhD – UCSF/Vitalant
Jeremy W Cannon, MD – U Penn (COL Ret.)
Andre Cap, MD PhD – (COL Ret.)
Kevin Chung, MD – SeaStar Medical (Col Ret.)
Charles S Cox, MD – UT
Kyle Cromer, PhD – UCSF
Joseph Cuschieri, MD – UCSF
Allan Doctor, MD – Univ of Maryland
Brian Eliceiri, PhD – UCSD
Eric Elster MD, FA CAPT (Ret)
Stephen Ferrari MD CAPT (Ret)
Michael Fitzpatrick, PhD – Cellphire Inc. (COL Ret.)
Jennifer Gurney, MD FACS – (COL US Army)
John B Holcomb, MD – UAB (COL Ret.)
Mary Homer, PhD – BARDA
Lucy Kornblith, MD FACS – UCSF
Sun Young Lee, MD, PhD – USC
Song Li PhD – UCLA
Geoffrey Ling, MD PhD – (COL Ret.)
Lester Martinez-Lopez, MD – fr ASDHA (MG Ret.)
Flora Momen-Heravi, DDS, PhD, MPH, MS – UCSF
Ernest “Gene” Moore, MD – CU Anschutz
Maj.Gen. Clinton K Murray MD
Matthew Neal, MD, FACS – UPitt
Jan Nolta, PhD – UC Davis
Lauren Palestrini PhD – MTEC
Shibani Pati, MD PhD – UCSF
Matthew Paszek, PhD – UCD
James B Peake, MD LTG (Ret)
Heather Pidcoke MD PhD – Vitrafy
Travis M. Polk, MD FACS – U Pitt (CAPT USN Ret)
Anthony Pusateri, PhD – Navy Medical Research 
Joseph Rappold, MD – Tufts Univ (CAPT Ret.)
Terry M. Rauch, PhD – ASDHA (COL. Ret.)
Susan Rowell, MD MBA – UChicago Medicine
Randy Schekman, PhD – UC Berkley
Martin Schreiber, MD – USU (COL USAR)
Brian Shy, MD PhD – UCSF
Jason Sperry, MD – UPMC
David Stroncek, MD – NIH
Mary Stuever, MD – Col USAF
Vice Admiral Darin K Via – DHA
Saul Villeda, PhD – UCSF
Daniel Waller, MD – UCSF
Arun Wiita, MD PhD – UCSF
Terese West, PhD – US Army Combat Casualty Care Research Unit

SIGNUP FOR MORE INFORMATION

Questions? Email us at [email protected] or call 303-238-0685